BREAKING NEWS: FDA advisory committee votes to NOT recommend approval of booster shots for Pfizer’s Covid vaccine
- The FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) has voted to not recommend approval of Covid vaccine booster shots
- The panel said there was not enough evidence that a third dose was safe and effective for use
- Pfizer said data suggested efficacy of two doses declines from 96.2% to 83.7% after six months but that a third dose boosts antibody levels
- FDA officials have previously expressed doubt about the need for extra doses and say the vaccines are still highly effective against severe disease and death
An independent panel at the U.S. Food and Drug Administration (FDA) has voted 16-2 to not recommend approval of booster doses for the Pfizer-BioNTech COVID-19 vaccine.
The Vaccines and Related Biological Products Advisory Committee (VRBPAC) said there was not enough evidence that a third dose was safe and effective for use at least six months after the final dose.
The FDA is not bound to follow the advisory group’s recommendations but the panel advising against approval makes it harder for the agency to justify moving forward.
Pfizer has submitted data that the company claims shows that its vaccine’s efficacy falls by about six percent evert two months following the second and final dose.
But many scientists, including senior officials at the FDA, disagree and argue that the vaccines are still highly effective at preventing severe illness and death.
The Vaccines and Related Biological Products Advisory Committee (VRBPAC) has voted to not recommend approval of the COVID-19 vaccine booster shots. Pictured: A nurse administers a COVID-19 booster shot to Lana Sellers in Altamonte Springs, Florida, August 18
This is a breaking news story and will be updated.